Physician profile
Suzanne Smith
NPI 1770510752
$1,381.75
in general payments reported to CMS, 2019-2025
15 companies · $492 in 2025
The $492 reported for 2025 was more than what 76% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.43 · 2020: $38.78 · 2021: $61.12 · 2022: $239 · 2023: $189 · 2024: $327 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,007.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $483.06 | 2023-2025 | Eylea Hd, Eylea |
| Coopervision INC. | $245.93 | 2022-2025 | Misight Contact Lens |
| Bausch & Lomb Americas INC. | $197.49 | 2022-2025 | Infuse, Biotrue One Day, Xipere |
| Dompe US, INC. | $154.19 | 2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $72.57 | 2020-2021 | |
| Alcon Vision LLC | $55.11 | 2019-2025 | Precision7 |
| Abbvie INC. | $34.87 | 2023-2024 | Ozurdex |
| Allergan, INC. | $21.77 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $21.35 | 2024 | Xdemvy |
| Omeros Corporation | $19.73 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $19.72 | 2022 | |
| Genentech USA, INC. | $15.01 | 2025 | Vabysmo |
| Horizon Therapeutics Plc | $14.87 | 2021 | |
| Abb Con-Cise Optical Group LLC | $13.62 | 2024 | Spectacle Lenses, Contact Lens |
| Sun Pharmaceutical Industries INC. | $12.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.